OBJECTIVE: This report describes the design and methodology of the Convergence Insufficiency Treatment Trial (CITT), the first large-scale, placebo-controlled, randomized clinical trial evaluating treatments for convergence insufficiency (CI) in children. We also report the clinical and demographic characteristics of patients. METHODS: We prospectively randomized children 9 to 17 years of age to one of four treatment groups: 1) home-based pencil push-ups, 2) home-based computer vergence/accommodative therapy and pencil push-ups, 3) office-based vergence/accommodative therapy with home reinforcement, 4) office-based placebo therapy. Outcome data on the Convergence Insufficiency Symptom Survey (CISS) score (primary outcome), near point of convergence (NPC), and positive fusional vergence were collected after 12 weeks of active treatment and again at 6 and 12 months posttreatment. RESULTS: The CITT enrolled 221 children with symptomatic CI with a mean age of 12.0 years (SD = +2.3). The clinical profile of the cohort at baseline was 9Delta exophoria at near (+/- 4.4) and 2Delta exophoria (+/-2.8) at distance, CISS score = 30 (+/-9.0), NPC = 14 cm (+/- 7.5), and near positive fusional vergence break = 13 Delta (+/- 4.6). There were no statistically significant nor clinically relevant differences between treatment groups with respect to baseline characteristics (p > 0.05). CONCLUSION: Hallmark features of the study design include formal definitions of conditions and outcomes, standardized diagnostic and treatment protocols, a placebo treatment arm, masked outcome examinations, and the CISS score outcome measure. The baseline data reported herein define the clinical profile of those enrolled into the CITT.
RCT Entities:
OBJECTIVE: This report describes the design and methodology of the Convergence Insufficiency Treatment Trial (CITT), the first large-scale, placebo-controlled, randomized clinical trial evaluating treatments for convergence insufficiency (CI) in children. We also report the clinical and demographic characteristics of patients. METHODS: We prospectively randomized children 9 to 17 years of age to one of four treatment groups: 1) home-based pencil push-ups, 2) home-based computer vergence/accommodative therapy and pencil push-ups, 3) office-based vergence/accommodative therapy with home reinforcement, 4) office-based placebo therapy. Outcome data on the Convergence Insufficiency Symptom Survey (CISS) score (primary outcome), near point of convergence (NPC), and positive fusional vergence were collected after 12 weeks of active treatment and again at 6 and 12 months posttreatment. RESULTS: The CITT enrolled 221 children with symptomatic CI with a mean age of 12.0 years (SD = +2.3). The clinical profile of the cohort at baseline was 9Delta exophoria at near (+/- 4.4) and 2Delta exophoria (+/-2.8) at distance, CISS score = 30 (+/-9.0), NPC = 14 cm (+/- 7.5), and near positive fusional vergence break = 13 Delta (+/- 4.6). There were no statistically significant nor clinically relevant differences between treatment groups with respect to baseline characteristics (p > 0.05). CONCLUSION: Hallmark features of the study design include formal definitions of conditions and outcomes, standardized diagnostic and treatment protocols, a placebo treatment arm, masked outcome examinations, and the CISS score outcome measure. The baseline data reported herein define the clinical profile of those enrolled into the CITT.
Authors: Mitchell Scheiman; Jeffrey Cooper; G Lynn Mitchell; Land Paul de; Susan Cotter; Eric Borsting; Richard London; Michael Rouse Journal: Optom Vis Sci Date: 2002-03 Impact factor: 1.973
Authors: Eric J Borsting; Michael W Rouse; G Lynn Mitchell; Mitchell Scheiman; Susan A Cotter; Jeffrey Cooper; Marjean Taylor Kulp; Richard London Journal: Optom Vis Sci Date: 2003-12 Impact factor: 1.973
Authors: Michael W Rouse; Eric J Borsting; G Lynn Mitchell; Mitchell Scheiman; Susan A Cotter; Jeffrey Cooper; Marjean T Kulp; Richard London; Janice Wensveen Journal: Ophthalmic Physiol Opt Date: 2004-09 Impact factor: 3.117
Authors: Annette Bade; Mark Boas; Michael Gallaway; G Lynn Mitchell; Mitchell Scheiman; Marjean T Kulp; Susan A Cotter; Michael Rouse Journal: Optom Vis Sci Date: 2013-09 Impact factor: 1.973
Authors: Jeffrey J Walline; Amber Gaume Giannoni; Loraine T Sinnott; Moriah A Chandler; Juan Huang; Donald O Mutti; Lisa A Jones-Jordan; David A Berntsen Journal: Optom Vis Sci Date: 2017-09 Impact factor: 1.973
Authors: Tara L Alvarez; Vincent R Vicci; Yelda Alkan; Eun H Kim; Suril Gohel; Anna M Barrett; Nancy Chiaravalloti; Bharat B Biswal Journal: Optom Vis Sci Date: 2010-12 Impact factor: 1.973
Authors: Mitchell Scheiman; Marjean Taylor Kulp; Susan Cotter; G Lynn Mitchell; Michael Gallaway; Mark Boas; Rachel Coulter; Kristine Hopkins; Susanna Tamkins Journal: Optom Vis Sci Date: 2010-08 Impact factor: 1.973
Authors: Michael Rouse; Eric Borsting; G Lynn Mitchell; Susan A Cotter; Marjean Kulp; Mitchell Scheiman; Carmen Barnhardt; Annette Bade; Tomohiko Yamada; Tomohike Yamada Journal: Optom Vis Sci Date: 2009-04 Impact factor: 1.973
Authors: Katherine K Weise; Mark W Swanson; Kimberly Penix; Matthew Heath Hale; Drew Ferguson Journal: Optom Vis Sci Date: 2017-01 Impact factor: 1.973